NuVasive, Inc. (NASDAQ:NUVA) has earned a consensus rating of “Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $81.18.
A number of equities analysts have recently weighed in on NUVA shares. Barclays PLC boosted their price target on NuVasive from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Monday, April 24th. Canaccord Genuity reissued a “buy” rating and issued a $84.00 price target (up from $82.00) on shares of NuVasive in a report on Wednesday, April 26th. Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. TheStreet raised NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $76.00 price target on shares of NuVasive in a report on Monday, May 15th.
Shares of NuVasive (NASDAQ NUVA) traded down 0.57% during mid-day trading on Friday, reaching $67.61. The company’s stock had a trading volume of 919,429 shares. The firm has a market capitalization of $3.43 billion, a P/E ratio of 106.47 and a beta of 1.06. NuVasive has a 1-year low of $56.70 and a 1-year high of $81.68. The company’s 50-day moving average is $73.23 and its 200 day moving average is $74.03.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. During the same period in the previous year, the firm posted $0.40 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts expect that NuVasive will post $2.00 earnings per share for the current year.
In other NuVasive news, EVP Peter Michael Leddy bought 7,850 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average cost of $63.88 per share, for a total transaction of $501,458.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.70% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. acquired a new position in NuVasive during the first quarter valued at approximately $109,000. FNY Partners Fund LP purchased a new stake in NuVasive during the first quarter worth about $112,000. Neuburgh Advisers LLC increased its stake in NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock worth $116,000 after buying an additional 240 shares during the period. SpiderRock Advisors LLC purchased a new stake in NuVasive during the first quarter worth about $124,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock worth $146,000 after buying an additional 158 shares during the period.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
What are top analysts saying about NuVasive Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NuVasive Inc. and related companies.